Overview

Alternatives for Reducing Chorea in Huntington Disease

Status:
Completed
Trial end date:
2017-08-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER. In addition, the safety and tolerability of long-term treatment with SD-809 ER will be assessed in "Switch" participants as well as "Rollover" participants completing a randomized, double blind, placebo-controlled study of SD-809 ER.
Phase:
Phase 3
Details
Lead Sponsor:
Auspex Pharmaceuticals, Inc.